Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer

Fumitaka Taniguchi, Akihiro Nyuya, Toshiaki Toshima, Kazuya Yasui, Yoshiko Mori, Makoto Okawaki, Hiroyuki Kishimoto, Yuzo Umeda, Toshiyoshi Fujiwara, Hiroaki Tanioka, Yoshiyuki Yamaguchi, Ajay Goel, Takeshi Nagasaka

Research output: Contribution to journalArticlepeer-review


Aim: To evaluate whether PCR-reverse sequence-specific oligonucleotide can examine the concordance between liquid biopsy and metastatic lesions with acquired resistance. Materials & methods: We examined acquired mutations in chemoresistant lesions and blood obtained from four patients with RAS wild-type metastatic colorectal cancer who underwent treatment with anti-epidermal growth factor receptor antibodies. Results: In one patient, metastatic lesions harbored diverse acquired mutations in KRAS in all seven metastases; the two acquired mutations were detectable in blood collected after the patient acquired resistance. None of the other patients exhibited liquid biopsy mutations, except one, with a BRAF mutation confirmed in primary tumor and peritoneal dissemination. Conclusion: Liquid biopsy based on PCR-reverse sequence-specific oligonucleotide is a successful procedure for capturing acquired mutations with precise information on the RAS mutational spectrum.

Original languageEnglish
Article number20210059
JournalFuture Science OA
Issue number10
Publication statusPublished - Dec 2021
Externally publishedYes


  • Acquired mutations
  • BRAF
  • PCR-rSSO
  • RAS
  • colorectal cancer
  • liquid biopsy

ASJC Scopus subject areas

  • Biotechnology


Dive into the research topics of 'Concordance of acquired mutations between metastatic lesions and liquid biopsy in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this